Oramed Pharmaceuticals And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl
I'm PortAI, I can summarize articles.
Oramed Pharmaceuticals and its unit have entered into a joint venture agreement with Hefei Tianhui Biotech and Technowl Limited. The joint venture aims to initiate a Phase 3 oral insulin trial in the US using Oramed's oral drug delivery technology. Hefei Tianhui Biotech will contribute $70 million in cash to the joint venture, while Oramed will contribute $20 million. The joint venture will focus on developing products based on Oramed's oral insulin and POD™ pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments